Actilyse\u00ae is the commercial brand name of Alteplase for Injection, developed by Boehringer Ingelheim. It is a recombinant tissue-type plasminogen activator. It binds to fibrin in thrombi to convert plasminogen into plasmin locally, dissolving occlusive thrombi without inducing systemic extensive fibrinolysis.<\/p>\n\n\n\n
Main Indications<\/strong> Clinical Research<\/strong> Common Side Effects<\/strong> Approval Status in China<\/strong> Buy Actilyse (Alteplase for Injection)\u00a0online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.<\/p>\n","protected":false},"excerpt":{"rendered":" Actilyse\u00ae is the commercial brand name of Alteplase for Injection, developed by Boehringer Ingelheim. It is a recombinant tissue-type plasminogen activator. It binds to fibrin in thrombi to convert plasminogen into plasmin locally, dissolving occlusive thrombi without inducing systemic extensive fibrinolysis. Main IndicationsTreatment of acute ischemic stroke within qualified therapeutic time window;Thrombolytic therapy for acute […]<\/p>\n","protected":false},"author":4,"featured_media":4448,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[101],"tags":[],"class_list":["post-4447","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-drug-news"],"blocksy_meta":[],"yoast_head":"\n
Treatment of acute ischemic stroke within qualified therapeutic time window;
Thrombolytic therapy for acute myocardial infarction;
Treatment of massive pulmonary embolism with hemodynamic instability.<\/p>\n\n\n\n
Global multicenter pivotal trials verified its thrombolytic efficacy and safety for critical vascular events. Stroke registration trials confirmed timely intravenous administration significantly improves neurological recovery and reduces permanent disability risk. Myocardial infarction comparative studies proved its ability to recanalize occluded coronary arteries and lower cardiac mortality. Pulmonary embolism observational trials demonstrated rapid resolution of pulmonary vascular obstruction and stabilization of hemodynamic parameters. Tolerability research showed bleeding as the primary relevant adverse event with controllable risk under standardized dosage and patient screening.<\/p>\n\n\n\n
Common mild adverse reactions: Minor superficial bleeding at puncture sites, ecchymosis;
Laboratory abnormalities: Transient decline of fibrinogen levels;
Severe but uncommon risks: Intracranial hemorrhage, severe gastrointestinal hemorrhage, anaphylactic shock and hypotension.<\/p>\n\n\n\n
Actilyse\u00ae (specification 50mg per vial, kit containing solvent and transfer set) obtained marketing approval in China in 1998. It is an injectable prescription emergency thrombolytic drug included in China\u2019s Category B medical insurance catalogue.<\/p>\n\n\n\n